• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

byNeel MistryandTeddy Guo
October 11, 2022
in Chronic Disease, Nephrology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Atezolizumab was associated with non-significantly increased disease-free survival compared to placebo (57.2 months vs. 49.5 months).

2. Serious adverse events were more numerically more common in atezolizumab (18%) versus placebo (12%).

Evidence Rating Level: 1 (Excellent)

Study Rundown: Surgery is the standard of care for localized renal cell carcinoma. Despite this, the 5-year recurrence post-resection remains high, ranging from 10% to 68%. Atezolizumab is an anti-programmed death-ligand 1 (PD-L1) antibody that may mitigate the risk of recurrence in patients with higher risk renal cell carcinomas. However, current research on its efficacy is limited. This randomized controlled trial aimed to determine the safety and efficacy of atezolizumab for post-resection recurrence in patients with renal cell carcinoma. The primary outcome was disease-free survival. According to study results, atezolizumab did not significantly improve disease-free survival in this cohort. Any-grade and high-grade adverse events were comparable between the treatment groups. This study was strengthened by a large sample size with patients from various countries, thus increasing its generalizability.

Click to read the study in The Lancet

Relevant Reading: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

In-depth [randomized-controlled trial]: Between Jan 3, 2017, and Feb 15, 2019, 1399 patients were screened for eligibility across 215 centers in 28 countries. Included were those aged ≥18 years with high risk of recurrence for renal cell carcinoma. Altogether, 778 patients (390 to atezolizumab and 388 to placebo) were included in the final analysis. The primary endpoint of disease-free survival was numerically greater in the atezolizumab group (57.2 months) compared to placebo (49.5 months), although this was not statistically significant (hazard ratio [HR] 0.93, 95% CI 0.75-1.15; p=0.50). The occurrence of grade 3-4 adverse events was similar between groups including hypertension (2% in atezolizumab vs. 4% in placebo), hyperglycemia (3% vs. 2%), and diarrhea (1% vs. 2%). Serious adverse events were more common in the atezolizumab group (18% vs. 12% in placebo); however, there were no reported treatment-related deaths. Findings from this study suggest that atezolizumab did not show improved clinical outcomes than placebo for post-resection recurrence in patients with renal cell carcinoma.

RELATED REPORTS

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

Empagliflozin use is associated with slower progression of chronic kidney disease

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced renal cell carcinomaanti-PD-L1anti-pd-l1 antibodyAtezolizumabimmunotherapymetastatic renal cell carcinomanephrologyoncologyrenal cell neoplasmrenal malignancyrenal-cell carcinoma
Previous Post

Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER

Next Post

Collaborative home-based palliative care approach effective for heart failure patients

RelatedReports

Intravenous contrast may not increase risk of acute kidney injury
Chronic Disease

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

February 3, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

Early-life body size not an independent risk factor for colorectal cancer

January 11, 2023
Next Post

Collaborative home-based palliative care approach effective for heart failure patients

Adding sargramostim to ipilimumab may improve survival in advanced melanoma

Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Wellness Check: Exercise

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis
  • Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease
  • College campus monkeypox outbreaks can be controlled with timely detection and isolation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options